The endeavor above results in novel cancer targets being discovered, such as the NRG1 or NRG2 fusion, RAS-GRF1 fusion,740 CLIP1-LTK fusion,741 UBA1 mutation,742 RICTOR, PINK1, L1RE1, ILF2 mutation and SBS40a or SBS22a mutation,743 as well as ATM (aurora kinase)-ATR (ataxia telangiectasia and rad3-related protein)-CHEK1 (checkpoint kinase 1), all of which will feature in the next step that drug development will take. Here, CHEK1 is linked to cancer.